{
    "relation": [
        [
            "Creatinine clearance (mL/min)/(mL/sec)",
            "> 20/0.33",
            "5\u201320/0.08\u20130.33",
            "< 5/0.08",
            "Chronic intermittent hemodialysis patients"
        ],
        [
            "Dose",
            "500 mg every 6 hours",
            "250 mg every 6 hours",
            "250 mg every 12 hours",
            "250 mg at the start of hemodialysis; 250 mg after 12 hours; and 250 mg 36\u201348 hours after start"
        ]
    ],
    "pageTitle": "Ceftin Drug Information, Professional",
    "title": "",
    "url": "http://www.drugs.com/mmx/ceftin.html",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988311.72/warc/CC-MAIN-20150728002308-00000-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 425180795,
    "recordOffset": 425092292,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{680145=Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex\u00ae (updated July 13th, 2015), Cerner Multum\u2122 (updated July 2nd, 2015), Wolters Kluwer\u2122 (updated July 2nd, 2015) and others. To view content sources and attributions, please refer to our editorial policy., 628853=Revised: 02/26/2003, 681422=Copyright \u00a9 2000-2015 Drugs.com. All rights reserved.}",
    "textBeforeTable": "Table 1. Pharmacology/Pharmacokinetics {59}4 Pharmacology/Pharmacokinetics 1\u00a0Not included in Canadian product labeling. {59}5 S. aureus . Staphylococcus epidermidis or Clostridium difficile , or methicillin-resistant Listeria species, chlamydia, None of the cephalosporins is considered to be effective against enterococci, Unaccepted 1\u2014Cefaclor is used in the treatment of sinusitis resistant to amoxicillin. [Sinusitis, amoxicillin-resistant (treatment)] {59}6. {59}7 {59}8 {59}9 {77}0 {77}1 {77}2 {77}3 {77}4 {77}5 B. pseudomallei has a high mortality rate. It is more common among adults, individuals with diabetes, and individuals with chronic renal disease, but it can occur in normal hosts and children. Melioidosis can reactivate years after primary infection and result in chronic or acute life-threatening disease. Melioidosis should be considered as a potential diagnosis for any patient with exposure to areas of endemicity Pseudomonas pseudomallei. It is endemic in areas of southeast Asia and the northern part of Australia. Melioidosis causes acute and chronic pulmonary disease, abscesses of the skin and internal organs, meningitis, brain abscess and cerebritis, and acute fulminant rapidly fatal sepsis. Infection with Burkholderia pseudomallei, previously known as \u2014Melioidosis is an infection with {77}6. {77}7 {77}8 {77}9 {27}0 {27}1 {27}2 {27}3 {27}4 {27}5 1\u2014Ceftazidime is indicated for the",
    "textAfterTable": "\u00a0 Cefadroxil\u00a0 95\u00a0 1.5\u00a0 20\u201325\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Oral\u00a0 \u00a0 \u00a0 \u00a0 1.5\u20132\u00a0 16\u00a0 500 mg \u00a0 1800\u00a0 500 mg\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 28\u00a0 1 gram\u00a0 \u00a0 \u00a0 Cefazolin\u00a0 \u00a0 1.4\u20132 *\u00a0 40\u201370\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 IM\u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}